LONDON, April 02, 2020 (GLOBE NEWSWIRE) -- Circadia Health announces $3 million in medical devices and services towards COVID-19 relief efforts across the globe. The company has expedited the release of the Contactless Respiratory Monitoring System (C100) to reduce the workload and risk of exposure on frontline health workers in the COVID-19 response. Circadia is committing to an immediate delivery of 2,000 devices and is on track to tripling their manufacturing capacity.

Circadia has started deploying its AI-powered C100 with a large hospital in Los Angeles and is in ongoing discussions with global governments and health systems.

“The demand for ventilators must be supplemented with the demand for remote monitoring of patients for early detection of respiratory distress. Circadia’s C100 uses AI-powered algorithms and alerts to identify potential worsening of lung function. We have now received exemption from the Malaysian government to ramp up production and are in communication with FDA for expedited review,” says Fares Siddiqui, Chief Executive Officer of Circadia Health.

“Managing and monitoring the influx of patients is overwhelming our global medical systems. Circadia’s proven remote respiratory monitoring of those potentially affected can help prioritize the clinical team’s resources. The need for hands-on review is minimized, with alerts of changes in respiration available if needed. The patients’ progress over time is summarized,” says Chief Medical Advisor, Professor Adrian Williams formerly at Harvard Medical School, UCLA, and former Director of the Lane Fox Respiratory Unit at Guys’ and St Thomas’ Hospital.

About Circadia Health

Circadia (https://circadia.health), HQ in London is a medical technology company enabling early detection of respiratory complications, the third leading cause of death, to save patient lives. Founded in 2016 by Imperial College London alumni Fares Siddiqui and Michal Maslik, Circadia employs engineers, scientists, and physicians to fuse hardware, software, and AI.